Catabasis Pharmaceuticals to Report Second Quarter 2020 Financial Results on Monday, August 10th

Catabasis Pharmaceuticals, Inc. CATB, a clinical-stage biopharmaceutical company, will report second quarter 2020 financial results after the Nasdaq Global Market close on Monday, August 10, 2020.

About Catabasis

At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our lead program is edasalonexent, an NF-kB inhibitor in Phase 3 development for the treatment of Duchenne muscular dystrophy. For more information on edasalonexent and our Phase 3 PolarisDMD trial, please visit www.catabasis.com.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Press Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!